Simvastatin reverses the downregulation of dopamine D1 and D2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats

Brain Research

Volumn 1045, Issue 1-2, 2005, Pages 229-233

  Wang, Q ^a   Wang, P H ^a   McLachlan, C ^a   Wong, P T H ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

6 OHDA lesion; Dopamine D1 and D2 receptors; Downregulation; Parkinson's disease (PD); Simvastatin, hydroxymethylglutaryl coenzyme A reductase inhibitor; Upregulation

Indexed keywords

DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; OXIDOPAMINE; SIMVASTATIN;

ANIMAL EXPERIMENT; ARTICLE; BRAIN INJURY; COGNITIVE DEFECT; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; DOWN REGULATION; DRUG RECEPTOR BINDING; FOREBRAIN; MALE; NONHUMAN; PARKINSONISM; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; RECEPTOR INTRINSIC ACTIVITY; RECEPTOR OCCUPANCY;

ANIMALS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEDIAL FOREBRAIN BUNDLE; OXIDOPAMINE; PARKINSONIAN DISORDERS; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECOVERY OF FUNCTION; SIMVASTATIN; SUBSTANTIA NIGRA; SYMPATHOLYTICS; TREATMENT OUTCOME;

EID: 19444382315     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2005.03.016     Document Type: Article

References (41)

1. 11C]raclopride Mov. Disord. 12 1997 33 38
2. T. Araki, H. Tanji, H. Kato, and Y. Itoyama Sequential changes of dopaminergic receptors in the rat brain after 6-hydroxydopamine lesions of the medial forebrain bundle J. Neurol. Sci. 160 1998 121 127
3. T. Araki, H. Tanji, H. Kato, Y. Imai, M. Mizugaki, and Y. Itoyama Temporal changes of dopaminergic and glutamatergic receptors in 6-hydroxydopamine-treated rat brain Eur. Neuropsychopharmacol. 10 2000 365 375
4. C.P. Cannon, E. Braunwald, C.H. McCabe, D.J. Rader, J.L. Rouleau, R. Belder, S.V. Joyal, K.A. Hill, M.A. Pfeffer, and A.M. Skene Pravastatin or atorvastatin evaluation and infection therapy-Thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes N. Engl. J. Med. 350 2004 1495 1504
5. 1 receptor stimulation Science 287 2000 2020 2022
6. J. Chen, Z.G. Zhang, Y. Li, Y. Wang, L. Wang, H. Jiang, C. Zhang, M. Lu, M. Katakowski, C.S. Feldkamp, and M. Chopp Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke Ann. Neurol. 53 2003 743 751
7. T.M. Dawson, V.L. Dawson, F.H. Gage, L.J. Fisher, M.A. Hunt, and J.K. Wamsley Functional recovery of supersensitivity dopamine receptors after intrastriatal grafts of fetal substantia nigra Exp. Neurol. 111 1991 282 292
8. B. Dubois, and B. Pillon Do cognitive changes of Parkinson's disease result from dopamine depletion? J. Neural Transm. 45 1995 27 34 [Suppl.]
9. S. El-Jack, and A. Kerr Secondary prevention in coronary artery disease patients in South Auckland: moving targets and the current treatment gap N. Z. Med. J. 116 2003 U664
10. M. Endres, U. Laufs, J.K. Liao, and M.A. Moskowitz Targeting eNOS for stroke protection Trends Neurosci. 27 2004 283 289
11. Y. He, P.S.P. Thong, T. Lee, S.K. Leong, C.Y. Shi, P.T.-H. Wong, S.Y. Yuan, and F. Watt Increased iron in the substantia nigra of 6-OHDA induced parkinsonian rats: a nuclear microscopy study Brain Res. 735 1996 149 153
12. K.H. Holm, F. Cicchetti, L. Bjorklund, Z. Boonman, P. Tandon, L.C. Costantini, T.W. Deacon, X. Huang, D.F. Chen, and O. Isacson Enhanced axonal growth from fetal human bcl-2 transgenic mouse dopamine neurons transplanted to the adult rat striatum Neuroscience 104 2001 397 405
13. N. Howard-Jones A CIOMS ethical code for animal experimentation WHO Chron. 39 1985 51 56
14. A.J. Hughes Clinicopathological aspects of Parkinson's disease Eur. Neurol. 38 Suppl. 2 1997 13 20
15. A.J. Hughes, S.E. Daniel, S. Blanston, and A.J. Lees The clinical features of Parkinson's disease: a clinicopathological study of 100 cases Arch. Neurol. 50 1993 140 148
16. H. Jick, G.L. Zornberg, S.S. Jick, S. Seshadri, and D.A. Drachman Statins and the risk of dementia Lancet 356 2000 1627 1631
17. 3 receptors in early and advanced Parkinson's disease Neurology 54 2000 1482 1487
18. 2 receptors in Parkinson's disease: a longitudinal study J. Neural Transm. 110 2003 591 601
19. J. Kulisevs.ky, C. Garcia-Sanchez, M.L. Berthier, M. Barbanoj, B. Pascual-Sedano, A. Gironell, and A. Estevez-Gonzalez Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients Mov. Disord. 15 2000 613 626
20. U. Laufs Beyond lipid-lowering: effects of statins on endothelial nitric oxide Eur. J. Clin. Pharmacol. 58 2003 719 731
21. M.R. Law, N.J. Wald, and A.R. Rudnicka Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis Br. Med. J. 326 2003 1423 1429
22. L.S. Loo, Y.K. Ng, Y.Z. Zhu, H.S. Lee, and P.T.-H. Wong Cortical expression of endothelin receptor subtypes A and B following middle cerebral artery occlusion in the rats Neuroscience 112 2002 993 1000
23. P.M. Mattila, M. Roytta, P. Lonnberg, P. Marjamaki, H. Helenius, and J.O. Rinne Choline acetytransferase activity and striatal dopamine receptors in Parkinson's disease in relation to cognitive impairment Acta Neuropathol. (Berlin) 102 2001 160 166
24. J.M. McKenney Potential nontraditional applications of statins Ann. Pharmacother. 37 2003 1063 1071
25. M.A. Mehta, B.J. Sahakian, P.J. McKenna, and T.W. Robbins Systemic sulpiride in young adult volunteers simulates the profile of cognitive deficits in Parkinson's disease Psychopharmacology 146 1999 162 174
26. 2 receptor binding and mRNA after 6-OHDA lesions of the medial forebrain bundle in the rat brain J. Chem. Neuroanat. 9 1995 41 53
27. 1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease Eur. J. Pharmacol. 114 1985 235 237
28. B. Reuss, and K. Unsicker Atypical neuroleptic drugs downregulate dopamine sensitivity in rat cortical and striatal astrocytes Mol. Cell. Neurosci. 18 2001 197 209
29. 2 receptor supersensitivity in the striatum of patients with early Parkinson's disease Mov. Disord. 5 1990 55 59
30. J.O. Rinne, A. Laihinen, P. Lonnberg, P. Marjamaki, and U.K. Rinne A post-mortem study on striatal dopamine receptors in Parkinson's disease Brain Res. 556 1991 117 122
31. 2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride J. Neurol. Sci. 132 1995 156 161
32. R.D. Rogers, B.J. Sahakian, J.R. Hodges, C.E. Polkey, C. Kennard, and T.W. Robbins Dissociating executive mechanisms of task control following frontal lobe damage and Parkinson's disease Brain 121 1998 815 842
33. J.S. Schneider, Z.Q. Sun, and D.P. Roeltgen Effects of dihydrexidine, a full dopamine D-1 receptor agonist, on delayed response performance in chronic low dose MPTP-treated monkeys Brain Res. 663 1994 140 144
34. L. Siever, R. Cohen, and A. Pert Assessing pharmacologically induced dopamine receptor sensitivity changes with the Ungerstedt turning model Psychopharmacology (Berlin) 75 1981 212 213
35. F. Tamaru Disturbances in higher function in Parkinson's disease Eur. Neurol. 38 Suppl. 2 1997 33 36
36. E.J. Topol Intensive statin therapy-A sea change in cardiovascular prevention N. Engl. J. Med. 350 2004 1562 1564
37. U. Ungerstedt 6-hydroxydopamine induced degeneration of central monoamine neurons Eur. J. Pharmacol. 5 1968 107 110
38. G.L. Vega, M.F. Weiner, A.M. Lipton, K. Von Bergmann, D. Lutjohann, C. Moore, and D. Svetlik Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease Arch. Neurol. 60 2003 510 515
39. 2 receptor expression in the rat prefrontal cortex: possible involvement of endothelial nitric oxide synthase, Br. J. Pharmacol. (in press) (Advanced online publication Feb. 14, 2005).
40. A. Zacco, J. Togo, K. Spence, A. Ellis, D. Lloyd, S. Furlong, and T. Piser 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity J. Neurosci. 23 2003 11104 11111
41. W.Q. Zhang, H.A. Tilson, K.P. Nanry, P.M. Hudson, J.S. Hong, and M.K. Stachowiak Increased dopamine release from striata of rats after unilateral nigrostriatal bundle damage Brain Res. 461 1988 335 342